The Corona Accelerated R&D in Europe (CARE) consortium today announced its launch to accelerate the development of COVID-19 treatments.
Supported by the Innovative Medicines Initiative, the new consortium has collected $92.7 million (€77.7 million) in grant funding in an effort to conduct a five-year project, bringing together 37 partners from Belgium, China, Denmark, France, Germany, the Netherlands, Poland, Spain, Switzerland, the UK and the U.S.
Leading the initiative is VRI-Inserm, Johnson & Johnson‘s (NYSE:JNJ) Janssen Pharmaceutical and Takeda Pharmaceutical (TSE:4502;NYSE:TAK) as the companies integrate partners’ COVID-19 projects that have been ongoing since February.
CARE aims to combine the researchers to accelerate the discovery and development of solutions for the current COVID-19 pandemic, as well as future coronavirus outbreaks, with the most promising drug candidates set to advance to clinical trials in humans after testing…